Stem Cell Agency Commits $150 Million to Develop New Therapies California’s stem cell agency, the California Institute for Regenerative Medicine approved $150 million in new funding to help move promising stem cell-based therapies from the laboratory research phase to clinical trials in people. [California Institute For Regenerative Medicine] Press Release U.S. National Institutes of Health to Support Development of Pluristem’s PLX-RAD Cells for Treatment of Acute Radiation Syndrome Pluristem Therapeutics, Inc. announced that it has received an invitation from the U.S. National Institute of Allergy and Infectious Diseases to submit its PLacental eXpanded (PLX) cells to the agency for evaluation in models of the acute radiation syndrome. [Pluristem Therapeutics, Inc.] Press Release Medical College of Wisconsin Researcher to Study New Treatment for Chronic Pain The Medical College of Wisconsin received a four-year, $1.1 million grant from the National Institutes of Health’s National Institute of Neurological Disorders and Stroke to study the use of genetically modified adult stem cells to treat neuropathic pain. [Medical College of Wisconsin] Press Release UTMB Scientists Awarded NIH Grant for Lab-Grown Lung Tissue Project University of Texas Medical Branch at Galveston (UTMB) researchers have been awarded a two-year, $1.25 million National Institutes of Health (NIH) grant to develop a method of custom-growing human lung tissue to make a three-dimensional model for biomedical studies. [EurekAlert!] Press Release Fraundhofer IZI Receives Official Certification for Manufacturing of Northwest Bio’s DCVax®-L Product Northwest Biotherapeutics, Inc. announced that its partner in Germany, Fraunhofer IZI, has received the official approval and certification from the regional and national regulatory agencies in Germany for the manufacture of Northwest Bio’s DCVax®-L immune therapy for human patients with Glioblastoma multiforme brain cancer. [Northwest Biotherapeutics, Inc.] Press Release Histogenics Closes $49 Million Series A Fundraising to Support Commercial Development of Transformational Cartilage Repair Products Histogenics Corporation announced the completion of a $49 million round of financing. Proceeds will be used to complete the ongoing Phase III clinical program for lead product candidate NeoCart®. Funds will also support efforts to obtain regulatory clearance in the European Union for product candidate VeriCart™, a cell-free collagen scaffold uniquely designed to be used in conjunction with the patient’s own stem cells, to repair small cartilage defects. [Histogenics Corporation] Press Release Roche and AREVA Med Join Forces in the Fight Against Cancer and Create a Novel Radio-Immunotherapy Roche and AREVA Med announced that they have entered into a strategic collaboration to create a novel, advanced alpha radio-immunotherapy platform to target and kill cancer cells. [AREVA] Press Release ACT Issued Broad Patent for Human RPE Cells Derived from All Types of Pluripotent Stem Cells Advanced Cell Technology, Inc. (ACT) announced that it has been issued a patent in Australia, patent number 2005325753, “Improved modalities for the treatment of degenerative diseases of the retina.” The patent broadly covers the use of human retinal pigment epithelial (RPE) cells generated from pluripotent stem cells in the manufacture of pharmaceutical preparations of RPE cells, and the use of those preparations to treat patients with degenerative diseases of the retina. [Advanced Cell Technology, Inc.] Press Release Neuralstem Receives Notice of Issuance for Patent Covering Human Neural Cell Transplantation for Neurodegenerative Conditions Neuralstem, Inc. announced that it received a notice of issuance for patent number 12/710,097 titled: “Transplantation of Human Neural Cells for Treatment of Neurodegenerative Conditions.” This patent covers both the culturing of central nervous system cells as well as their transplantation into spinal cord tissue to treat neurodegenerative conditions. [Neuralstem, Inc.] Press Release |